

Hypothesis Testing in Healthcare: Drug Safety

A pharmaceutical company GlobalXYZ has just completed a randomized controlled drug trial. To promote transparency and reproducibility of the drug's outcome, they (GlobalXYZ) have presented the dataset to your organization, a non-profit that focuses primarily on drug safety.

The dataset provided contained five adverse effects, demographic data, vital signs, etc. Your organization is primarily interested in the drug's adverse reactions. It wants to know if the adverse reactions, if any, are of significant proportions. It has asked you to explore and answer some questions from the data.

The dataset `drug_safety.csv` was obtained from [Hbiostat](#) courtesy of the Vanderbilt University Department of Biostatistics. It contained five adverse effects: headache, abdominal pain, dyspepsia, upper respiratory infection, chronic obstructive airway disease (COAD), demographic data, vital signs, lab measures, etc. The ratio of drug observations to placebo observations is 2 to 1.

For this project, the dataset has been modified to reflect the presence and absence of adverse effects `adverse_effects` and the number of adverse effects in a single individual `num_effects`.

The columns in the modified dataset are:

Column	Description
<code>sex</code>	The gender of the individual
<code>age</code>	The age of the individual
<code>week</code>	The week of the drug testing
<code>trx</code>	The treatment (Drug) and control (Placebo) groups
<code>wbc</code>	The count of white blood cells
<code>rbc</code>	The count of red blood cells
<code>adverse_effects</code>	The presence of at least a single adverse effect
<code>num_effects</code>	The number of adverse effects experienced by a single individual

The original dataset can be found [here](#).

- **Determine if the proportion of adverse effects differs significantly between the Drug and Placebo groups:**

Null Hypothesis (H0): The proportion of adverse effects is the same in the Drug and Placebo groups.

Alternative Hypothesis (H1): The proportion of adverse effects is different between the Drug and Placebo groups.

Chi-square test is a statistical test used to compare observed results with expected results. The purpose of this test is to determine if a difference between observed data and expected data is due to chance, or if it is due to a relationship between the variables you are studying.

Case Processing Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
trx_group * adverse_effects_group	16103	100.0%	0	0.0%	16103	100.0%

trx_group * adverse_effects_group Crosstabulation

		adverse_effects_group		Total
		No	Yes	
trx_group	Placebo	4864	512	5376
	Drug	9703	1024	10727
Total		14567	1536	16103

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.002 ^a	1	.964		
Continuity Correction ^b	.000	1	.987		
Likelihood Ratio	.002	1	.964		
Fisher's Exact Test				.976	.493
Linear-by-Linear Association	.002	1	.964		
N of Valid Cases	16103				

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 512.79.

b. Computed only for a 2x2 table

Analysis Summary

p-value = 0.964; significance level = 0.05

A chi-square test was used to compare the rates of side effects between two groups: the Drug group and the Placebo group. The test gave a p-value of 0.964, while the chosen significance level was 0.05.

Since the p-value (0.964) is higher than the significance level (0.05), the decision is to **not reject the null hypothesis**. This result suggests that there is no meaningful difference in the rates of side effects between the Drug and Placebo groups.

What it means: With a p-value of 0.964, the results show there is no significant difference in the rates of side effects between the Drug and Placebo groups. The small difference we see in the data is likely just by chance, rather than showing a real difference between the groups.

In simple terms, the chi-square test did not find enough evidence to conclude that the rates of side effects are different between the two groups. The null hypothesis, which assumes no difference in the rates, cannot be rejected based on the available data.

- **Find out if the number of adverse effects is independent of the treatment and control groups.**

Null Hypothesis (H0): There is no relationship between the number of adverse effects and treatment and control groups

Alternative Hypothesis (H1): There is a relationship between the two variables.

The Chi-Square Test of Independence determines whether there is an association between categorical variables (i.e., whether the variables are independent or related). It is a nonparametric test. This test is also known as: **Chi-Square Test of Association**.

num_effects * trx_group Crosstabulation

% within num_effects

		trx_group		
		Placebo	Drug	Total
num_effects	0	33.4%	66.6%	100.0%
	1	33.7%	66.3%	100.0%
	2	28.4%	71.6%	100.0%
	3	16.7%	83.3%	100.0%
Total		33.4%	66.6%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	1.800 ^a	3	.615
Likelihood Ratio	1.922	3	.589
Linear-by-Linear Association	.138	1	.710
N of Valid Cases	16103		

a. 2 cells (25.0%) have expected count less than 5. The minimum expected count is 2.00.

I used a chi-square test to check if the number of adverse effects was related to the treatment group or the control group. The test gave a **p-value of 0.615**, and the **significance level was set at 0.05**.

Since the p-value (0.615) is higher than the significance level (0.05), we cannot reject the null hypothesis. This means the data does not show a clear connection between the number of adverse effects and whether someone was in the treatment group or the control group.

In simple terms, based on this test, **the adverse effects seem to happen regardless of which group someone was in - the treatment group or the control group.**

Symmetric Measures

		Value	Asymptotic Standard Error ^a	Approximate T ^b	Approximate Significance
Ordinal by Ordinal	Gamma	.002	.028	.074	.941
	Spearman Correlation	.001	.008	.074	.941 ^c
Interval by Interval	Pearson's R	.003	.008	.371	.710 ^c
N of Valid Cases		16103			

a. Not assuming the null hypothesis.


b. Using the asymptotic standard error assuming the null hypothesis.

c. Based on normal approximation.

The Gamma coefficient measures the strength of association between two ordinal variables. A **Gamma coefficient value is 0.002**, which is very close to 0, indicates that there is little or no association between the two ordinal variables. It suggests that the **variables are independent or have a negligible relationship.**

A **Spearman's correlation coefficient value is 0.001**, which is very close to 0, indicating a negligible correlation between the two variables. It suggests that the variables are **nearly independent or have a very weak monotonic relationship**.

In summary, the statements correctly interpret the values of the Gamma coefficient and Spearman's correlation coefficient as being very close to 0, which does imply independence or a lack of association between the variables being analyzed.



- **Examine if there is a significant difference between the ages of the Drug and Placebo groups:**

I use the Kolmogorov-Smirnov test of normality and check normality for the Drug and Placebo groups.

H0: the sample data follows the **normal** distribution

H1: the sample data NOT follows the **normal** distribution

Descriptives



trx_group			Statistic	Std. Error
age	Placebo	Mean	63.97	.121
		95% Confidence Interval for Mean	Lower Bound	63.73
			Upper Bound	64.21
		5% Trimmed Mean	64.27	
		Median	65.00	
		Variance	79.086	
		Std. Deviation	8.893	
		Minimum	39	
		Maximum	84	
		Range	45	
		Interquartile Range	13	
		Skewness	-.454	.033
		Kurtosis	-.396	.067
	Drug	Mean	64.19	.084
		95% Confidence Interval for Mean	Lower Bound	64.03
			Upper Bound	64.36
		5% Trimmed Mean	64.50	
		Median	65.00	
		Variance	76.163	
		Std. Deviation	8.727	
		Minimum	39	
		Maximum	82	
		Range	43	
		Interquartile Range	13	
		Skewness	-.474	.024
		Kurtosis	-.266	.047

Tests of Normality

		Kolmogorov-Smirnov ^a		
age	trx_group	Statistic	df	Sig.
	Placebo	.078	5376	<.001
	Drug	.070	10727	<.001

a. Lilliefors Significance Correction



The p-value = <.0001 is less than the chosen significance level 0.05, I **reject the null hypothesis**. This means that **the data does NOT follow the normal distribution**.






A **normal Q-Q (quantile-quantile) plot** is a graphical method used to assess whether a data set follows a normal distribution or not.

If the points on the Q-Q plot make an almost straight line, it means the data is likely normally distributed. The closer the points are to the straight line, the stronger the evidence that the data follows a normal distribution.

A **detrended Q-Q plot** is a variation of the normal Q-Q plot used to assess normality in a dataset. The main difference is that a detrended Q-Q plot accounts for and removes any potential trend or shift in the data before evaluating its normality.







Summarization:

Based on the visual inspection of the graphics for the Placebo and Drug groups, we can see that the data is not normally distributed.

Independent-Samples Mann-Whitney U Test

The Independent-Samples Mann-Whitney U Test is a **non-parametric** statistical test used to compare the distributions of two **independent samples**.

H0: There is **NO** significant difference between the age distributions of the Drug and Placebo groups

H1: There is significant difference between the age distributions of the Drug and Placebo groups

Hypothesis Test Summary			
	Null Hypothesis	Test	Sig. ^{a,b}
1	The distribution of age is the same across categories of trx_group.	Independent-Samples Mann-Whitney U Test	.257
	Decision		
	Retain the null hypothesis.		

a. The significance level is .050.

b. Asymptotic significance is displayed.

Summarization:

The p-value of 0.257 is higher than the significance level of 0.05. The Mann-Whitney U test result shows there is **no important difference in the ages between the Drug group and the Placebo group**. This means age is likely not an important factor separating the two treatment groups.